-----



# **Urgent Field Safety Notice**

FSN-FA-2019-04.1 June 2019

A Siemens Healthineers Company

### Adaptation of FTD Lyophilized products shelf life after first opening- ADDDENDUM

------

#### Dear customer,

The purpose of this follow-up communication is to provide additional information related to FSN-FA-2019-04 issued earlier this month.

### **Details on affected product:**

Please find here below, as per FSN-FA-2019-04, the list of affected products.

Table 1: List of products affected by FSN-FA-2019-04

Catalogue	Product name	
number		
FTlyo-2	FTlyo Respiratory pathogens 21	
FTlyo-2+.1	FTlyo Respiratory pathogens 21 plus	
FTlyo-2P.3	FTlyo Respiratory pathogens 33	
FTlyo-13	FTlyo Viral meningitis	
FTlyo-21.1	FTlyo FLU	
FTlyo-23	FTIyo EPA	
FTlyo-43	FTlyo Dengue/Chik	
FTlyo-48.1	FTIyo FLU/HRSV	
FTlyo-56.1	FTIyo HCoV	
FTlyo-65.2	FTIyo HPIV	
FTlyo-86	FTlyo Respiratory pathogens 16	

Please note that this FSN is <u>not lot specific</u>, but it applies to all produced batches for the above-mentioned kits.

### Update on the stability data:

Please note that the stability of the lyophilized product depends on the storage condition of you lyophilised pouches. The Table 2 below contains stability data related to the temperature storage of the pouches.

Table 2: Shelf life of products after first opening, depending of storage conditions.

Catalogue number	Product name	Shelf life after first opening of pouches at 2 to 8°C	Shelf life after first opening of pouches at -30 to -10°C, as stated in manuals
FTlyo-2	Ftlyo Respiratory pathogens 21	9 months	12 months
FTlyo-2+.1	FTlyo Respiratory pathogens 21 plus	9 months	12 months
FTlyo-2P.3	FTIyo Respiratory pathogens 33	9 months	12 months
FTlyo-13	FTlyo Viral meningitis	9 months	12 months
FTlyo-21.1	FTlyo FLU	3 months	12 months
FTlyo-23	FTIyo EPA	9 months	12 months
FTlyo-43	FTlyo Dengue/Chik	3 months	12 months
FTlyo-48.1	FTIyo FLU/HRSV	3 months	12 months
FTlyo-56.1	FTIyo HCoV	9 months	12 months
FTlyo-65.2	FTIyo HPIV	3 months	12 months
FTlyo-86	FTIyo Respiratory pathogens 16	3 months	12 months

NOTE: All open and closed pouches should not be used beyond the expiration date written on the kit box.

For the risk assessment, please refer to FSN-FA-2019-04.

FSN-FA-2019-04.1 Page **1** of **2** 

# Fast Track >>> DIAGNOSTICS

Urgent Field Safety Notice FSN-FA-2019-04.1 June 2019

**A Siemens Healthineers Company** 

### Adaptation of FTD Lyophilized products shelf life after first opening- ADDDENDUM

-----

### Actions to be taken by distributors:

Please forward relevant information to your impacted end-users and send us back the annex #1 "Field Correction Effectiveness Check" of this FSN to <a href="mailto:vigilance@fast-trackdiagnostics.com">vigilance@fast-trackdiagnostics.com</a> for the 15th of July 2019.

Please retain this letter with your laboratory records and forward this letter to those who may have received this product.

If you have any questions, please contact FTD at: <a href="mailto:support@fast-trackdiagnostics.com">support@fast-trackdiagnostics.com</a>.

Fast Track Diagnostics assays are manufactured by Fast Track Diagnostics S.à.r.l. and Fast Track Diagnostics is a registered trademark of Fast Track Diagnostics Ltd.

FSN-FA-2019-04.1 Page **2** of **2** 

### FIELD CORRECTION EFFECTIVENESS CHECK

## Adaptation of FTD Lyophilized products shelf life after first opening- ADDDENDUM

This response form is to confirm receipt of the enclosed Fast Track Diagnostics Urgent Field Safety Notification FSN-FA-2019-04.1, dated June 2019 regarding "Adaptation of FTD Lyophilized products shelf life after first opening- ADDDENDUM". Please read each statement and indicate the appropriate answer.

Email this completed form to the email address provided at the bottom of this page, by the 15<sup>th</sup> of July 2019.

	I have read and understood the Field Safety Notice instructions provided in this letter.	Yes □	No □	
(	I am a distributor of the affected products AND my customers received one of the products impacted by this FSN	Yes □	No □	
If the answer to statement 2 above is yes, please confirm that Yes \( \square \) you forward the relevant information to your impacted customers.				
Name of	person completing questionnaire:			
Title:	portion completing queetiennane.			
Institutio	n:			
Street:				
City:		State:		
Phone:		Country:		
		·		
	Signature			
	and date			
	2.10 4.40			

Please send a scanned copy of the completed form via email to <a href="mailto:vigilance@fast-trackdiagnostics.com">vigilance@fast-trackdiagnostics.com</a>.

If you have any questions, contact a Fast Track Diagnostics support representative.